Literature DB >> 9334731

Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.

S Stilgenbauer1, C Schaffner, A Litterst, P Liebisch, S Gilad, A Bar-Shira, M R James, P Lichter, H Döhner.   

Abstract

Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterized by cerebellar ataxia, oculocutaneous telangiectasia, immune deficiency, genome instability and predisposition to malignancies, particularly T-cell neoplasms. The responsible gene, designated ataxia-telangiectasia mutated (ATM), was recently identified by positional cloning in the chromosomal region 11q22.3-23.1 (ref. 4, 5) ATM is 150 kb in length, consists of 66 exons and encodes a nuclear phosphoprotein of approximately 350 kDa (ref. 4-9). Although ATM is considered to be a tumorigenic factor in several human cancers, it has not yet been found mutated in tumors of non-AT patients. Given the marked predisposition of AT patients to develop neoplasms of the T-cell lineage, we analyzed a series of T-cell leukemias (T-prolymphocytic leukemia, or T-PLL) in non-AT patients in search of genomic changes associated with the development of this disease. Among the recurrent aberrations identified, deletion of the chromosome arm 11q was very frequent. Subsequent molecular cytogenetic analyses allowed us to define a small commonly deleted segment at 11q22.3-23.1 in 15 of 24 T-PLLs studied. Since this critical region contained ATM, we further analyzed the remaining copy of the gene in six cases showing deletions affecting one ATM allele. In all six cases, mutations of the second ATM allele were identified, leading to the absence, premature truncation or alteration of the ATM gene product. Thus, our study demonstrates disruption of both ATM alleles by deletion or point mutation in T-PLL, suggesting that ATM functions as a tumor-suppressor gene in tumors of non-AT individuals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334731     DOI: 10.1038/nm1097-1155

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  36 in total

1.  Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Authors:  C Schaffner; I Idler; S Stilgenbauer; H Döhner; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 2.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 3.  T-cell prolymphocytic leukemia.

Authors:  Claire E Dearden
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy.

Authors:  Daniel Nowak; Emilie Le Toriellec; Marc-Henri Stern; Norihiko Kawamata; Tadayuki Akagi; Martin J Dyer; Wolf-Karsten Hofmann; Seishi Ogawa; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

Review 5.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

Review 6.  Molecular pathology of ataxia telangiectasia.

Authors:  A M R Taylor; P J Byrd
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 7.  ATM, radiation, and the risk of second primary breast cancer.

Authors:  Jonine L Bernstein; Patrick Concannon
Journal:  Int J Radiat Biol       Date:  2017-07-27       Impact factor: 2.694

8.  T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:  Geling Li; Emily Waite; Julie Wolfson
Journal:  Blood Adv       Date:  2017-12-18

9.  Importance of ATM gene as a susceptible trait: predisposition role of D1853N polymorphism in breast cancer.

Authors:  Parvin Mehdipour; Marzieh Mahdavi; Javad Mohammadi-Asl; Morteza Atri
Journal:  Med Oncol       Date:  2010-04-16       Impact factor: 3.064

Review 10.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.